The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996

O’Reilly, Seamus; Rowinsky, Eric K.

doi:10.1016/1040-8428(96)00211-9

Cited by 59 publications

(26 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31,40 We expected a combination regimen of CPT-11 and cisplatin to have an activity superior to the individual agents alone against mesothelioma. We achieved a major objective response rate of 26.7% and an overall response rate of 40% when two regressions in evaluable disease were also included.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma

Nakano

Chahinian

Shinjo

et al. 1999

Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma

Nakano

Chahinian

Shinjo

et al. 1999

Cancer

View full text Add to dashboard Cite

“…Most of the phase I studies of irinotecan have given 90 min infusions every week for 3 to 4 weeks or once every 3 weeks (Masuda et al [83] and O'Reilly et al [84]). The use of irinotecan has been explored less in children; schedules in this group have included a 120 hr infusion [85] and a daily infusion for 5 days [86].…”

Section: Clinical Studies Of Irinotecan Phase I Studiesmentioning

confidence: 98%

Clinical use of topoisomerase I inhibitors in anticancer treatment

Rodríguez‐Galindo

Radomski

Stewart

et al. 2000

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

The camptothecin analogs topotecan and irinotecan have shown to be among the most effective anticancer agents and, as S-phase specific agents, their antitumor effect is maximized when they are administered in protracted schedules. The documented activity as single agents in many adult and pediatric malignancies has been followed by their use in combination with other anticancer agents. These studies have shown promising results, and have placed topotecan and irinotecan in the first line treatment for some malignancies. However, studies to better determine the optimal schedules and sequence of combinations are needed.

show abstract

“…Irinotecan appears to exert its antineoplastic activity via the inhibition of the nuclear enzyme topoisomerase I, and phase II studies have shown that the drug is active in NSCLC (Boisseau et al, 1996;O'Reilly and Rowinski, 1996). An additive or synergistic effect for the combination of irinotecan and cisplatin (CDDP) has also been described (Kano et al, 1992;Kudoh et al, 1993).…”

mentioning

confidence: 99%

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

et al. 2005

View full text Add to dashboard Cite

The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) pretreated with a taxane/gemcitabine regimen. Patients (n ¼ 147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive either irinotecan (110 mg m À2 , day 1 and 100 mg m À2 , day 8) and cisplatin (80 mg m À2 , day 8) (IC; n ¼ 74) or CDDP (80 mg m À2 , day 1) (C; n ¼ 73) every 3 weeks. Patients treated with IC and C had a median survival of 7.8 and 8.8 months, respectively (P ¼ 0.933). The 1-year survival rate was 34.3% for IC-treated patients and 31.7% for C-treated patients. Cox's regression analysis revealed that response to treatment (hazard ratio (HR) ¼ 2.787; 95% confidence interval (CI): 1.1578 -4.922) and performance status (HR ¼ 1.865; 95% CI: 1.199 -2.872) was independent prognostic factors for survival. Overall response rate was 22.5% (95% CI: 12.8 -32.2%) for IC-treated patients and 7.0% (95% CI: 1.15 -13.6%) for C-treated patients (P ¼ 0.012); tumour growth control (partial remission (PR) þ stable disease (SD)) was observed in 26 (38%) IC and 25 (36%) C patients (P ¼ 0.878). There was no difference in terms of quality of life between the two chemotherapy arms. The incidence of febrile neutropenia, grade 3 and 4 neutropenia and grade 3 and 4 diarrhoea was significantly higher in the IC-than the C-treated patients. Other toxicities were mild. There were no treatment-related deaths in either arm. The IC regimen did not confer a survival benefit compared with C as second-line treatment of patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen, despite its better efficacy in terms of response rate.

show abstract

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996

Cited by 59 publications

References 78 publications

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma

Clinical use of topoisomerase I inhibitors in anticancer treatment

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study

Contact Info

Product

Resources

About